The histiocytosis Erdheim–Chester disease is an inflammatory myeloid neoplasm

References

• Chester W. Über. Lipoidgranulomatose. Virchows Arch Pathol Anat 1930;279:561-602
   Google Scholar
• Adam Z, Koukalova R, Sprlakova A, et al. Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review. Vnitr Lek 2011;57:576-89
   PubMedGoogle Scholar
• Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012;24:53-9
   PubMed Web of Science ®Google Scholar
• Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117:2778-82
   PubMed Web of Science ®Google Scholar
• Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014;124:483-92
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) 2004;83:371-92
   PubMed Web of Science ®Google Scholar
• Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 1996;75:157-69
   PubMed Web of Science ®Google Scholar
• Brower AC, Worsham GF, Dudley AH. Erdheim-Chester disease: a distinct lipoidosis or part of the spectrum of histiocytosis? Radiology 1984;151:35-8
   PubMed Web of Science ®Google Scholar
• Tsai JW, Tsou JH, Hung LY, et al. Combined Erdheim-Chester disease and Langerhans cell histiocytosis of skin are both monoclonal: a rare case with human androgen-receptor gene analysis. J Am Acad Dermatol 2010;63:284-91
   PubMed Web of Science ®Google Scholar
• Wang KH, Cheng CJ, Hu CH, et al. Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai-Dorfman disease. Br J Dermatol 2002;147:770-4
   PubMed Web of Science ®Google Scholar
• Hervier B, Haroche J, Arnaud L, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 2014;124:1119-26
   PubMed Web of Science ®Google Scholar
• Balink H, Hemmelder MH, de Graaf W, et al. Scintigraphic diagnosis of Erdheim-Chester disease. J Clin Oncol 2011;29:e470-2
   Google Scholar
• Haroche J, Amoura Z, Wechsler B, et al. [Erdheim-Chester disease]. Presse Med 2007;36:1663-8
   PubMed Web of Science ®Google Scholar
• Andre M, Delevaux I, de Fraissinette B, et al. Two enlarged kidneys: a manifestation of Erdheim-Chester disease. Am J Nephrol 2001;21:315-17
   PubMed Web of Science ®Google Scholar
• Dion E, Graef C, Haroche J, et al. Imaging of thoracoabdominal involvement in Erdheim-Chester disease. AJR Am J Roentgenol 2004;183:1253-60
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006;54:3330-6
   PubMed Web of Science ®Google Scholar
• Jeon IS, Lee SS, Lee MK. Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer 2010;55:745-7
   PubMed Web of Science ®Google Scholar
• Tran TA, Fabre M, Pariente D, et al. Erdheim-Chester disease in childhood: a challenging diagnosis and treatment. J Pediatr Hematol Oncol 2009;31:782-6
   PubMed Web of Science ®Google Scholar
• Arnaud L, Malek Z, Archambaud F, et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum 2009;60:3128-38
   PubMed Web of Science ®Google Scholar
• Stenova E, Steno B, Povinec P, et al. FDG-PET in the Erdheim-Chester disease: its diagnostic and follow-up role. Rheumatol Int 2012;32:675-8
   PubMed Web of Science ®Google Scholar
• Dion E, Graef C, Miquel A, et al. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology 2006;238:632-9
   PubMed Web of Science ®Google Scholar
• Serratrice J, Granel B, De Roux C, et al. "Coated aorta": a new sign of Erdheim-Chester disease. J Rheumatol 2000;27:1550-3
   PubMed Web of Science ®Google Scholar
• Gupta A, Kelly B. McGuigan JE. Erdheim-Chester disease with prominent pericardial involvement: clinical, radiologic, and histologic findings. Am J Med Sci 2002;324:96-100
   PubMed Web of Science ®Google Scholar
• Haroche J, Cluzel P, Toledano D, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 2009;119:e597-8
   Google Scholar
• Fink MG, Levinson DJ, Brown NL, et al. Erdheim-Chester disease. Case report with autopsy findings. Arch Pathol Lab Med 1991;115:619-23
   PubMed Web of Science ®Google Scholar
• Loeffler AG, Memoli VA. Myocardial involvement in Erdheim-Chester disease. Arch Pathol Lab Med 2004;128:682-5
   PubMed Web of Science ®Google Scholar
• Kenn W, Stabler A, Zachoval R, et al. Erdheim-Chester disease: a case report and literature overview. Eur Radiol 1999;9:153-8
   PubMed Web of Science ®Google Scholar
• Alper MG, Zimmerman LE, Piana FG. Orbital manifestations of Erdheim-Chester disease. Trans Am Ophthalmol Soc 1983;81:64-85
   PubMedGoogle Scholar
• Sheidow TG, Nicolle DA, Heathcote JG. Erdheim-Chester disease: two cases of orbital involvement. Eye (Lond) 2000;14:606-12
   PubMed Web of Science ®Google Scholar
• Khamseh ME, Mollanai S, Hashemi F, et al. Erdheim-Chester syndrome, presenting as hypogonadotropic hypogonadism and diabetes insipidus. J Endocrinol Invest 2002;25:727-9
   PubMed Web of Science ®Google Scholar
• Tritos NA, Weinrib S, Kaye TB. Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis). J Intern Med 1998;244:529-35
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Touraine P, et al. Bilateral adrenal infiltration in Erdheim-Chester disease. Report of seven cases and literature review. J Clin Endocrinol Metab 2007;92:2007-12
   PubMed Web of Science ®Google Scholar
• Opie KM, Kaye J, Vinciullo C. Erdheim-Chester disease. Australas J Dermatol 2003;44:194-8
   PubMedGoogle Scholar
• Droupy S, Attias D, Eschwege P, et al. Bilateral hydronephrosis in a patient with Erdheim-Chester disease. J Urol 1999;162:2084-5
   PubMed Web of Science ®Google Scholar
• Arnaud L, Pierre I, Beigelman-Aubry C, et al. Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum 2010;62:3504-12
   PubMed Web of Science ®Google Scholar
• Brun AL, Touitou-Gottenberg D, Haroche J, et al. Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol 2010;20:2579-87
   PubMed Web of Science ®Google Scholar
• Lachenal F, Cotton F, Desmurs-Clavel H, et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J Neurol 2006;253:1267-77
   PubMed Web of Science ®Google Scholar
• Drier A, Haroche J, Savatovsky J, et al. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology 2010;255:586-94
   PubMed Web of Science ®Google Scholar
• Sheu SY, Wenzel RR, Kersting C, et al. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol 2004;57:1225-8
   PubMed Web of Science ®Google Scholar
• Provenzano E, Barter SJ, Wright PA, et al. Erdheim-chester disease presenting as bilateral clinically malignant breast masses. Am J Surg Pathol 2010;34:584-8
   PubMed Web of Science ®Google Scholar
• Johnson TR, Lenhard MS, Weidinger M, et al. An unusual breast tumor. Radiologe 2009;49:942-5
   PubMedGoogle Scholar
• Guo S, Yan Q, Rohr J, et al. Erdheim-Chester disease involving the breast-a rare but important differential diagnosis. Hum Pathol 2015;46:159-64
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harbouring the BRAF V600E mutation. Blood 2013;121:1495-500
   PubMed Web of Science ®Google Scholar
• Myra C, Sloper L, Tighe PJ, et al. Treatment of erdheim-chester disease with cladribine: a rational approach. Br J Ophthalmol 2004;88:844-7
   PubMed Web of Science ®Google Scholar
• Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med 2001;135:844-5
   PubMed Web of Science ®Google Scholar
• Gaspar N, Boudou P, Haroche J, et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica 2006;91:1121-8
   PubMed Web of Science ®Google Scholar
• Braiteh F, Boxrud C, Esmaeli B, et al. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 2005;106:2992-4
   PubMed Web of Science ®Google Scholar
• Janku F, Amin HM, Yang D, et al. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol 2010;28:e633-6
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008;111:5413-15
   PubMed Web of Science ®Google Scholar
• Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010;116:4070-6
   PubMed Web of Science ®Google Scholar
• Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012;30:e286-90
   PubMed Web of Science ®Google Scholar
• Gianfreda L, Nicastro M, Galetti M, et al. Sirolimus plus prednisone for Erdheim-Chester disease: an open-label, prospective trial. Blood 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005;23:6771-90
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
   PubMed Web of Science ®Google Scholar
• Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919-23
   PubMed Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120:2700-3
   PubMed Web of Science ®Google Scholar
• Emile JF, Charlotte F, Amoura Z, et al. BRAF Mutations in Erdheim-Chester Disease. J Clin Oncol 2013;31:398
   PubMed Web of Science ®Google Scholar
• Dietrich S, Glimm H, Andrulis M, et al. BRAF Inhibition in Refractory Hairy-Cell Leukemia. N Engl J Med 2012;366:2038-40
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated erdheim-chester disease. J Clin Oncol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Cohen-Aubart F, Emile JF, Maksud P, et al. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology 2014;83:1294-6
   PubMed Web of Science ®Google Scholar
• Diamond EL, Abdel-Wahab O, Pentsova E, et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood 2013;122:1089-91
   PubMed Web of Science ®Google Scholar
• Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 2006;54:4018-22
   PubMed Web of Science ®Google Scholar
• Dagna L, Girlanda S, Langheim S, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford) 2010;49:1203-6
   PubMed Web of Science ®Google Scholar
• Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011;117:2783-90
   PubMed Web of Science ®Google Scholar
• Emile JF, Diamond EL, Hélias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 2014;124:3016-19
   PubMed Web of Science ®Google Scholar
• Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar